Podium 05
2020-08-236. Room 202
09:00 ~ 09:10PD05-1: Factor evaluation of chemotherapy-naïve Enzalutamide on castration - resistant prostate cancer patients—Taiwanese cohort余秉軒張英勛, 林子平
09:10 ~ 09:20PD05-2: Tumor volume, time to PSA nadir and PSA decline rate influence outcomes in metastatic prostate cancer receiving androgen deprivation therapy林晏頎張英勛, 林子平
09:20 ~ 09:30PD05-3: Pathological node-positive renal cell carcinoma is associated with worse survival outcome: A recall for TMN staging revision陳思遠張英勛, 林子平
09:30 ~ 09:40PD05-4: Active contour model of machine learning to evlauate the kidney cancer盧致誠張英勛, 林子平
09:40 ~ 09:50PD05-5: The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: Systemic review and meta-analysis謝博彥張英勛, 林子平
09:50 ~ 10:00PD05-6: Combined immune checkpoint inhibitors in the frontline treatment of metastatic renal cell carcinoma—a real-world experience陳鵬張英勛, 林子平